# Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

> **NCT05291390** · PHASE2 · UNKNOWN · sponsor: **Armaceutica, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)

## Interventions

- **DRUG:** Pyronaridine Tetraphosphate

## Key facts

- **NCT ID:** NCT05291390
- **Lead sponsor:** Armaceutica, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-21
- **Primary completion:** 2024-02
- **Final completion:** 2024-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291390, "Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05291390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*